BACKGROUND: Chronic kidney disease is characterised by low estimated glomerular filtration rate (eGFR) and high albuminuria, and is associated with adverse outcomes. Whether these risks are modified by diabetes is unknown. METHODS: We did a meta-analysis of studies selected according to Chronic Kidney Disease Prognosis Consortium criteria. Data transfer and analyses were done between March, 2011, and June, 2012. We used Cox proportional hazards models to estimate the hazard ratios (HR) of mortality and end-stage renal disease (ESRD) associated with eGFR and albuminuria in individuals with and without diabetes. FINDINGS: We analysed data for 1,024,977 participants (128,505 with diabetes) from 30 general population and high-risk cardiovascular cohorts and 13 chronic kidney disease cohorts. In the combined general population and high-risk cohorts with data for all-cause mortality, 75,306 deaths occurred during a mean follow-up of 8·5 years (SD 5·0). In the 23 studies with data for cardiovascular mortality, 21,237 deaths occurred from cardiovascular disease during a mean follow-up of 9·2 years (SD 4·9). In the general and high-risk cohorts, mortality risks were 1·2-1·9 times higher for participants with diabetes than for those without diabetes across the ranges of eGFR and albumin-to-creatinine ratio (ACR). With fixed eGFR and ACR reference points in the diabetes and no diabetes groups, HR of mortality outcomes according to lower eGFR and higher ACR were much the same in participants with and without diabetes (eg, for all-cause mortality at eGFR 45 mL/min per 1·73 m(2) [vs 95 mL/min per 1·73 m(2)], HR 1·35; 95% CI 1·18-1·55; vs 1·33; 1·19-1·48 and at ACR 30 mg/g [vs 5 mg/g], 1·50; 1·35-1·65 vs 1·52; 1·38-1·67). The overall interactions were not significant. We identified much the same findings for ESRD in the chronic kidney disease cohorts. INTERPRETATION: Despite higher risks for mortality and ESRD in diabetes, the relative risks of these outcomes by eGFR and ACR are much the same irrespective of the presence or absence of diabetes, emphasising the importance of kidney disease as a predictor of clinical outcomes. FUNDING: US National Kidney Foundation.
BACKGROUND: Chronic kidney disease is characterised by low estimated glomerular filtration rate (eGFR) and high albuminuria, and is associated with adverse outcomes. Whether these risks are modified by diabetes is unknown. METHODS: We did a meta-analysis of studies selected according to Chronic Kidney Disease Prognosis Consortium criteria. Data transfer and analyses were done between March, 2011, and June, 2012. We used Cox proportional hazards models to estimate the hazard ratios (HR) of mortality and end-stage renal disease (ESRD) associated with eGFR and albuminuria in individuals with and without diabetes. FINDINGS: We analysed data for 1,024,977 participants (128,505 with diabetes) from 30 general population and high-risk cardiovascular cohorts and 13 chronic kidney disease cohorts. In the combined general population and high-risk cohorts with data for all-cause mortality, 75,306 deaths occurred during a mean follow-up of 8·5 years (SD 5·0). In the 23 studies with data for cardiovascular mortality, 21,237 deaths occurred from cardiovascular disease during a mean follow-up of 9·2 years (SD 4·9). In the general and high-risk cohorts, mortality risks were 1·2-1·9 times higher for participants with diabetes than for those without diabetes across the ranges of eGFR and albumin-to-creatinine ratio (ACR). With fixed eGFR and ACR reference points in the diabetes and no diabetes groups, HR of mortality outcomes according to lower eGFR and higher ACR were much the same in participants with and without diabetes (eg, for all-cause mortality at eGFR 45 mL/min per 1·73 m(2) [vs 95 mL/min per 1·73 m(2)], HR 1·35; 95% CI 1·18-1·55; vs 1·33; 1·19-1·48 and at ACR 30 mg/g [vs 5 mg/g], 1·50; 1·35-1·65 vs 1·52; 1·38-1·67). The overall interactions were not significant. We identified much the same findings for ESRD in the chronic kidney disease cohorts. INTERPRETATION: Despite higher risks for mortality and ESRD in diabetes, the relative risks of these outcomes by eGFR and ACR are much the same irrespective of the presence or absence of diabetes, emphasising the importance of kidney disease as a predictor of clinical outcomes. FUNDING: US National Kidney Foundation.
Authors: Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh Journal: Kidney Int Date: 2011-02-02 Impact factor: 10.612
Authors: Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli Journal: JAMA Date: 2010-02-03 Impact factor: 56.272
Authors: Areef Ishani; Greg A Grandits; Richard H Grimm; Kenneth H Svendsen; Allan J Collins; Ronald J Prineas; James D Neaton Journal: J Am Soc Nephrol Date: 2006-04-12 Impact factor: 10.121
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: V Menon; X Wang; M J Sarnak; L H Hunsicker; M Madero; G J Beck; A J Collins; J W Kusek; A S Levey; T Greene Journal: Kidney Int Date: 2008-03-12 Impact factor: 10.612
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: W Greg Miller; David E Bruns; Glen L Hortin; Sverre Sandberg; Kristin M Aakre; Matthew J McQueen; Yoshihisa Itoh; John C Lieske; David W Seccombe; Graham Jones; David M Bunk; Gary C Curhan; Andrew S Narva Journal: Clin Chem Date: 2008-11-21 Impact factor: 8.327
Authors: Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Marije van der Velde; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Marije van der Velde; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Meguid El-Nahas; Kai-Uwe Eckardt; Bertram L Kasiske; Jackson Wright; Larry Appel; Tom Greene; Adeera Levin; Ognjenka Djurdjev; David C Wheeler; Martin J Landray; John N Townend; Jonathan Emberson; Laura E Clark; Alison Macleod; Angharad Marks; Tariq Ali; Nicholas Fluck; Gordon Prescott; David H Smith; Jessica R Weinstein; Eric S Johnson; Micah L Thorp; Jack F Wetzels; P J Blankestijn; A D van Zuilen; Vandana Menon; Mark Sarnak; Gerald Beck; Florian Kronenberg; Barbara Kollerits; Marc Froissart; Benedicte Stengel; Marie Metzger; Giuseppe Remuzzi; Piero Ruggenenti; Annalisa Perna; H J Lambers Heerspink; Barry Brenner; Dick de Zeeuw; Peter Rossing; Hans-Henrik Parving; Priscilla Auguste; Kasper Veldhuis; Yaping Wang; Laura Camarata; Beverly Thomas; Tom Manley Journal: Kidney Int Date: 2011-02-02 Impact factor: 10.612
Authors: Bakhtawar K Mahmoodi; Kunihiro Matsushita; Mark Woodward; Peter J Blankestijn; Massimo Cirillo; Takayoshi Ohkubo; Peter Rossing; Mark J Sarnak; Bénédicte Stengel; Kazumasa Yamagishi; Kentaro Yamashita; Luxia Zhang; Josef Coresh; Paul E de Jong; Brad C Astor Journal: Lancet Date: 2012-09-24 Impact factor: 79.321
Authors: David M J Naimark; Morgan E Grams; Kunihiro Matsushita; Corri Black; Iefke Drion; Caroline S Fox; Lesley A Inker; Areef Ishani; Sun Ha Jee; Akihiko Kitamura; Janice P Lea; Joseph Nally; Carmen Alicia Peralta; Dietrich Rothenbacher; Seungho Ryu; Marcello Tonelli; Hiroshi Yatsuya; Josef Coresh; Ron T Gansevoort; David G Warnock; Mark Woodward; Paul E de Jong Journal: J Am Soc Nephrol Date: 2015-12-11 Impact factor: 10.121
Authors: Emin Murat Akbas; Aysu Timuroglu; Adalet Ozcicek; Fatih Ozcicek; Levent Demirtas; Adem Gungor; Nergis Akbas Journal: Int J Clin Exp Med Date: 2014-12-15
Authors: Kunihiro Matsushita; Shoshana H Ballew; Josef Coresh; Hisatomi Arima; Johan Ärnlöv; Massimo Cirillo; Natalie Ebert; Jade S Hiramoto; Heejin Kimm; Michael G Shlipak; Frank L J Visseren; Ron T Gansevoort; Csaba P Kovesdy; Varda Shalev; Mark Woodward; Florian Kronenberg Journal: Lancet Diabetes Endocrinol Date: 2017-07-14 Impact factor: 32.069
Authors: Benjamin M Scirica; Ofri Mosenzon; Deepak L Bhatt; Jacob A Udell; Ph Gabriel Steg; Darren K McGuire; KyungAh Im; Estella Kanevsky; Christina Stahre; Mikaela Sjöstrand; Itamar Raz; Eugene Braunwald Journal: JAMA Cardiol Date: 2018-02-01 Impact factor: 14.676
Authors: Dominik Steubl; Markus P Schneider; Heike Meiselbach; Jennifer Nadal; Matthias C Schmid; Turgay Saritas; Vera Krane; Claudia Sommerer; Seema Baid-Agrawal; Jakob Voelkl; Fruzsina Kotsis; Anna Köttgen; Kai-Uwe Eckardt; Jürgen E Scherberich Journal: Clin J Am Soc Nephrol Date: 2020-04-14 Impact factor: 8.237
Authors: Ian H de Boer; Leila R Zelnick; Julie Lin; Debra Schaumberg; Lu Wang; John Ruzinski; Georgina Friedenberg; Julie Duszlak; Vadim Y Bubes; Andrew N Hoofnagle; Ravi Thadhani; Robert J Glynn; Julie E Buring; Howard D Sesso; JoAnn E Manson Journal: Contemp Clin Trials Date: 2018-09-30 Impact factor: 2.226